Skip to main content

Cannabis: Medical Treatments

Question for Home Office

UIN 26081, tabled on 2 July 2021

To ask the Secretary of State for the Home Department, what the evidential basis is for cannabis-based products for medical use to be placed alongside fentanyl and diamorphine in Schedule 2 of the Misuse of Drugs Regulations 2001; and if she will make an assessment of the potential merits of placing such products in lower schedule such as Schedule 4.1 alongside Sativex.

Answered on

7 July 2021

In February 2019, the then Home Secretary commissioned the ACMD to conduct a longer-term review of Cannabis-Based Products for Medicinal use (CBPM). The ACMD published their report on 27 November 2020 on In it they recommended:

“that the scheduling of CBPMs under Schedule 2 of the MDR remains appropriate and that no further legislative amendments to the MDR regarding CBPMs are required at this point in time.”

Unlike Sativex, most CBPM do not have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). As such, in the absence of the reassurance that a CBPM has gone through the safety, quality and efficacy process established by the MHRA, it is right that it is in Schedule 2 of the Misuse of Drugs Regulations 2001. However, should a cannabis-based medicine receive a marketing authorisation from the MHRA, the Government will commission the Advisory Council on the Misuse of Drugs (ACMD) to reconsider the scheduling of the product under the Misuse of Drugs Regulations 2001. This was the case for Sativex following its marketing authorisation.

Answered by

Home Office
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.
Interests declared
The Member has declared that they have interests which may be relevant to the subject matter of this question.